Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Taxes (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Taxes for 15 consecutive years, with $335000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Taxes rose 245.36% to $335000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$134000.0, a 120.15% decrease, with the full-year FY2025 number at -$134000.0, down 120.15% from a year prior.
  • Change in Taxes was $335000.0 for Q4 2025 at Anika Therapeutics, up from -$21000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $1.3 million in Q2 2022 to a low of -$1.2 million in Q1 2021.
  • A 5-year average of $59350.0 and a median of -$17000.0 in 2025 define the central range for Change in Taxes.
  • Peak YoY movement for Change in Taxes: crashed 848.19% in 2021, then skyrocketed 800.0% in 2024.
  • Anika Therapeutics' Change in Taxes stood at -$888000.0 in 2021, then surged by 214.19% to $1.0 million in 2022, then crashed by 58.38% to $422000.0 in 2023, then crashed by 77.01% to $97000.0 in 2024, then surged by 245.36% to $335000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Change in Taxes are $335000.0 (Q4 2025), -$21000.0 (Q3 2025), and -$435000.0 (Q2 2025).